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Leptomeningeal collateral flow has been considered an im-portant determinant of clinical outcome in patients with 
acute ischemic stroke. Poor collateral status has been asso-
ciated with larger follow-up infarct volumes, increased mor-
tality, and poor functional outcome.1–5 Collateral circulation 
may prevent the penumbra, at least temporarily, to become 
infarcted by maintaining a certain level of cerebral blood flow. 
It has been shown that patients with absent collateral flow 
benefit less from endovascular treatment (EVT).6–9 As a result, 
several guidelines already recommend collateral status as a 
method to select patients for EVT.10,11
Little is known about the biological mechanisms that leads 
to the variability in filling pattern of leptomeningeal collaterals. 
Genetic factors have been suggested to be the strongest deter-
minants of collateral strength.12 Previous studies demonstrated 
that higher age, diabetes mellitus, history of hypertension, 
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high systolic blood pressure, location of the occlusion, pres-
ence of extracranial internal carotid artery (ICA) stenosis and 
poor hydration status are related to worse collateral status.13–18 
Further research on potential determinants for poor collat-
eral status could improve our understanding of the collateral 
system. Possibly, this might help to find ways to improve col-
lateral status during acute ischemic stroke and thus increase 
chances of a better clinical outcome.
In this study, we aim to identify clinical and imaging 
determinants that are associated with collateral status on base-
line computed tomography angiography in patients with acute 
ischemic stroke due to a proximal intracranial occlusion in the 
anterior circulation.
Methods
The data of the MR CLEAN trial (Multicenter Randomized Clinical 
Trial of Endovascular Treatment for Acute Ischemic Stroke in 
the Netherlands) have been made publicly available at the Virtual 
International Stroke Trials Archive and can be accessed at http://
www.virtualtrialsarchives.org/vista/. Individual patient data of the 
MR CLEAN Registry cannot be made available under Dutch law, as 
we did not obtain patient approval for sharing individual patient data, 
even in coded form. However, all syntax files and output of statistical 
analyses will be made available upon reasonable request.
We used data from the MR CLEAN and the MR CLEAN Registry. 
Patient selection criteria and methods of the MR CLEAN trial have 
been reported previously.19 In short, MR CLEAN was a randomized 
clinical trial of EVT with usual care (intervention group) versus usual 
care alone (control group) in patients (n=500) with a proximal intra-
cranial arterial occlusion in the anterior circulation demonstrated on 
vessel imaging, treatable within 6 hours after symptom onset. Study-
specific inclusion criteria were the presence of an occlusion of the 
ICA, intracranial carotid artery terminus (ICA-T), middle cerebral ar-
tery (M1 or M2), or anterior cerebral artery (A1 or A2), as confirmed 
on computed tomography angiography (CTA).19,20
The MR CLEAN Registry is an ongoing, prospective, multicenter, 
observational monitoring study, including all consecutive patients 
treated with EVT in the Netherlands since the final inclusion in the 
MR CLEAN trial. The aim of the MR CLEAN Registry is to monitor 
the safety and clinical practice of EVT in a well-defined set of patients, 
who are comparable to the patients in the MR CLEAN trial.21 Overall, 
1628 patients were registered in the MR CLEAN Registry between 
March 16, 2014 and June 15, 2016. For the current analysis, we applied 
the same inclusion criteria as in the MR CLEAN trial and therefore 
we excluded 140 patients, mostly because of occlusion in the posterior 
circulation or treatment starting after 6.5 hours from the onset of symp-
toms (Figure I in the Data Supplement). A total of 1488 patients from 
the MR CLEAN Registry were available for final analysis.
Assessment of Collateral Status
Collateral assessment was performed by 10 observers (each assessed 
100–200 different CTAs) from the MR CLEAN Registry imaging 
core laboratory, who were blinded to the clinical findings. All observ-
ers were provided with a training set including relevant definitions. 
Collateral status was graded on single-phase CTA source images on a 
4-point scale according to the visual collateral score using the method 
of Tan et al, with grade 0 for absent collaterals (0% filling of the oc-
cluded vascular territory), grade 1 for poor collaterals (>0% and ≤50% 
filling of the occluded vascular territory), grade 2 for moderate (>50% 
and <100% filling of the occluded vascular territory), and grade 3 
for good collaterals (100% filling of the occluded vascular territory; 
Figure 1). This score has shown to be a prognostic marker for outcome.
Clinical and Imaging Parameters
We analyzed patient and imaging characteristics that are expected 
to influence collateral status, based on expert opinion and recent 
literature. These included age, sex, level of glucose at baseline, his-
tory of atrial fibrillation, previous ischemic stroke, diabetes mellitus, 
hypercholesterolemia, hypertension, peripheral arterial disease, my-
ocardial infarction, smoking, systolic and diastolic blood pressures, 
the current use of statins, antihypertensive drugs and antiplatelets, 
extracranial carotid stenosis, location of occlusion, and time from 
symptom onset to CTA. We distinguished 2 subgroups for occlusion 
location: one subgroup included ICA or ICA-T occlusions, and the 
other included a segment of the middle cerebral artery and/or anterior 
cerebral artery.
Acquisition Phase
In an earlier study, CTA acquisition phase appeared to be signifi-
cantly associated with collateral status.22 The CTA acquisition phase 
is evaluated by comparing peak arterial opacification with peak ve-
nous opacification. An observer measured the opacification of the 
contralateral internal carotid artery and the transverse sinus and clas-
sified all CTA studies into one of the 5 acquisitions: early arterial 
(arterial Hounsfield units [HU] higher than venous structure, and 
venous structure ≤200 HU), peak arterial (arterial HU ≥100 higher 
than venous structure and venous structure >200 HU), equilibrium 
(arterial HU <100 higher or equal to venous structure and venous 
structure >200 HU), peak venous (arterial HU >200 and venous struc-
ture higher than artery), or late venous (arterial HU ≤200 and venous 
vessel higher than artery).23
Statistical Analysis
To assess potential nonlinearity of the relation between continuous 
variables and outcome, we used restricted cubic splines. Ordinal lo-
gistic regression analyses were used to test the effect of the selected 
determinants on the collateral status. The following analyses were 
performed:
Step 1:  univariable analysis with adjustment for CTA acquisition 
phase24
Step 2:  univariable analysis of all determinants with a P value 
<0.15 in Step 1, adjusted for age, sex, and CTA acquisi-
tion phase
Step 3:  multivariable analysis of all determinants with a P Value 
of P<0.05 in Step 2, adjusted for study (MR CLEAN trial 
or MR CLEAN Registry) and CTA acquisition phase.
We performed sensitivity analyses by repeating the analyses in all 
patients with a M1 or M2 occlusion, after dichotimization of the col-
lateral score into good (grade 2+3) and poor (grade 0+1), in patients 
who were scanned in acquisition phases 3 or 4, and in women and 
men separately.
All reported P values are 2-sided. Missing values were imputed 
with multiple imputation on the combined dataset, using the 
AregImpute function in R statistical software. The imputations (also 
for missing collateral status) were performed per study (MR CLEAN 
trial or -Registry) based on relevant covariates and outcome (Table II 
in the Data Supplement). Statistical analyses were performed in the R 
software environment (Version 3.2.2 or higher, the R Foundation for 
Statistical Computing, Vienna, Austria).
Results
Patient Characteristics
All 500 patients from the MR CLEAN trial (December 2010 
to March 2014) and 1488 patients from the MR CLEAN 
Registry database (March 2014 to June 2016), in total 1988 
patients, were included in this analysis. Distribution of the 
collateral status was as follows: grade 0 (7%, n=123), grade 
1 (31.8%, n=596), grade 2 (39.1%, n=734), grade 3 (22.5%, 
n=422).
Baseline characteristics are reported in Table 1. The median 
age of the total population was 69 years (interquartile range, 
58–79) and 1086 patients (55%) were men. In 113 patients 
(5.7%), the collateral status was not assessed (Table I in the Data 
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Supplement), and therefore 1875 patients were eligible for anal-
ysis. In total, 1639 values (3.9%) were missing at baseline and 
subsequently imputed. Except for time to CTA (n=1351, 68%) 
and smoking status (n=1645, 83%), all other determinants were 
in >95% complete (Table II in the Data Supplement).
Acquisition Phase
Distribution of the acquisition phase was as follows: phase 
1 (25.7%, n=483), phase 2 (16.4%, n=308), phase 3 (27.2%, 
n=510), phase 4 (20.2%, n=380), and phase 5 (10.5%, n=197). 
In phase 1, more patients had a collateral grade of 1 compared 
with other phases. Most patients whom were scanned during 
phase 3 or phase 4 had a collateral grade of 2 (Figure 2).
Associations With Collateral Status
The following determinants had a P value <0.15 in Step 1 and 
were therefore considered in Step 2: age, sex, diastolic and 
systolic blood pressures, glucose level, a history of hypercho-
lesterolemia, hypertension, myocardial infarction, peripheral 
arterial disease and ischemic stroke, the use of statins, anti-
platelets and antihypertensives, ICA-T occlusion, and time to 
CTA (Table 2). None of the continuous variables appeared to 
be nonlinear.
After adjustment for, age, sex, and CTA acquisition phase 
in Step 2, diastolic blood pressure, glucose, history of periph-
eral arterial disease, and occlusion in the ICA-(T) were signif-
icantly associated with collateral status (Table 2).
An independent association with worse collateral status in 
Step 3 was observed for higher age (adjusted common odds 
ratio, 0.92 [95% CI, 0.86–0.98] per 10 years, P=0.01), men 
(adjusted common odds ratio, 0.64 [95% CI, 0.53–0.83], 
P=0.76), higher glucose levels (adjusted common odds ratio, 
0.97 [95% CI 0.95–1.00] per mmol/L, P=0.02), and an occlu-
sion of the ICA-T segment (adjusted common odds ratio, 0.50 
[95% CI, 0.41–0.61], P<0.001) in the multivariable model 
(Table 2; Figure II in the Data Supplement).
No additional determinants could be identified in sensi-
tivity analysis in patients with an M1 or M2 occlusion, after 
dichotimization of the collateral score, or patients who were 
scanned in acquisition phase 3 or 4. Reanalysis in men and 
women separately revealed that in men, age and glucose 
were no longer associated with collateral status, but the use 
of antiplatelets was associated with worse collateral status. In 
Figure 1. Collateral score grading for each category of the 4-point scale. Left hemisphere was affected in all examples above. A, Grade 0, representing ab-
sent collaterals (0% filling of the occluded territory). B, Grade 1, representing poor collaterals (>0% and ≤50% filling of the occluded territory). C, Grade 2, 
representing moderate (>50% and <100% filling of the occluded territory). D, Grade 3, representing good collaterals (100% filling of the occluded territory).
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women, age was no longer associated with collateral status, 
but a history of peripheral arterial disease was associated with 
worse collateral status (Table III in the Data Supplement).
Discussion
In this analysis, we found that worse collateral status in 
patients with acute ischemic stroke with a large vessel occlu-
sion was associated with the following clinical and imaging 
determinants: higher age, male, glucose level at baseline, and 
ICA-T occlusion segment.
The results of our multivariable analysis suggest that a 
higher age has a direct negative effect on collateral status. A 
possible explanation has been described as pruning of collater-
als with increasing age, involving a decline in vessel diameter 
and increase in vessel tortuosity.25 Previous studies suggested 
that the association of age and collateral status is mediated 
through other age-related factors such as hyperlipidemia or 
systolic blood pressure.12,21 However, we did not find an effect 
of systolic blood pressure or a history of hypercholesterolemia 
on collateral status.
Table 1. Clinical and Imaging Characteristics at Baseline per Collateral Status
Total (n=1988) Grade 0 (n=123) Grade 1 (n=596) Grade 2 (n=734) Grade 3 (n=422) P Value
Clinical       
  Age, y; median (IQR) 69 (58–79) 72 (60–79) 71 (61–80) 68 (58–78) 67 (56–77) <0.001
  Men, no. (%) 1086 (55) 81 (66) 355 (60) 392 (53) 199 (47) <0.001
  NIHSS; median (IQR) 16 (12–20) 19 (15–23) 18 (14–22) 16 (12–19) 14 (10–18) <0.001
  SBP, mm Hg; mean (SD) 149 (25) 154 (25) 149 (25) 148 (25) 148 (24) 0.04
  DBP, mm Hg; mean (SD) 82 (15) 85 (15) 82 (16) 81 (15) 81 (16) 0.01
  Glucose at baseline, mmol/L; median (IQR) 6.7 (5.9–8.0) 7.1 (6.0–8.5) 6.8 (6.0– 8.1) 6.7 (5.8– 7.9) 6.5 (5.8–7.8) 0.01
  Atrial fibrillation, n (%) 462 (24) 34 (28) 134 (23) 180 (25) 87 (21) 0.24
  Hypercholesterolemia, n (%) 560 (29) 35 (29) 185 (32) 192 (27) 111 (27) 0.19
  Hypertension, n (%) 973 (49) 59 (48) 315 (53) 334 (46) 199 (48) 0.06
  Diabetes mellitus, n (%) 323 (16) 26 (21) 91 (15) 120 (16) 61 (15) 0.33
  Myocardial infarction, n (%) 302 (15) 19 (16) 100 (17) 107 (15) 54 (13) 0.34
  Peripheral artery disease, n (%) 159 (8.1) 8 (6.6) 66 (11) 58 (8.0) 22 (5.3) 0.01
  Ischemic stroke, n (%) 304 (15) 21 (17) 108 (18) 104 (14) 54 (13) 0.08
Prestroke modified Rankin Scale score, n (%) 0.10
  0 1395 (71) 81 (68) 409 (69) 524 (72) 302 (73)  
  1 240 (12) 19 (16) 64 (11) 90 (12) 51 (12)  
  2 135 (6.9) 10 (8) 47 (8) 46 (6) 24 (6)  
  >2 190 (10) 10 (8) 69 (12) 65 (9) 39 (9)  
Current smoking, n (%) 481 (29) 27 (22) 146 (25) 180 (25) 113 (27) 0.50
Statin use, n (%) 666 (34) 44 (36) 232 (40) 221 (30) 128 (31) <0.01
Antiplatelet use, n (%) 638 (32) 37 (30) 235 (40) 209 (29) 121 (29) <0.001
Antihypertensive medication use, n (%) 1004 (51) 59 (50) 338 (57) 353 (49) 194 (47) <0.01
Intravenous alteplase treatment, n (%) 1607 (81) 95 (77) 485 (81) 598 (81) 338 (80) 0.52
Imaging       
Level of occlusion on noninvasive vessel imaging, n (%) <0.001
  ICA 86 (4.5) 2 (1.6) 21 (3.5) 31 (4.3) 27 (6.4)  
  ICA-T 447 (23) 46 (37) 176 (30) 157 (22) 64 (15)  
  M1 1144 (60) 63 (51) 333 (56) 452 (61) 271 (64)  
  M2 214 (11) 12 (10) 60 (10) 88 (12) 52 (12)  
ASPECTS on NCCT—median (IQR) 9 (7–10) 8 (6–10) 8 (7–10) 9 (7–10) 9 (8–10) <0.001
Other       
  Time from onset to CTA—median (IQR) 105 (72–171) 106 (66–183) 99 (72–160) 104 (72–174) 115 (80–189) 0.23
Collateral status was missing in 113 patients. We performed χ2 test for categorical variables and ANOVA and Kruskal-Wallis testing for continuous variables. CTA 
indicates computed tomography angiography; DBP, diastolic blood pressure; ICA, intracranial carotid artery; ICA-T, intracranial carotid artery terminus; IQR, interquartile 
range; NCCT, noncontract computerized tomography; NIHSS, National Institutes of Health Stroke Scale; and SBP, systolic blood pressure.
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We found poorer collateral status in men then in women, 
although it is reported that women have worse stroke outcomes 
than men. The main explanation for these sex differences are 
said to be attributable to a difference in sex hormones.26–28 
Sex differences in the collateral circulation in mice have been 
investigated by a recent study. However, the authors con-
cluded that the cerebral collateral circulation was not different 
between male and female mice.29 Further research is needed 
to investigate possible anatomic differences related to cerebral 
collaterals between men and women.
We found an association of a higher level of glucose at 
baseline and worse collateral status. Among patients without 
a history of diabetes mellitus, admission hyperglycemia may 
be resulting from previously undiagnosed diabetes mellitus 
or glucose intolerance, stress response mediated by cortisol 
and noradrenaline, or combination of these.30,31 Earlier studies 
showed that hyperglycemia, whether acute or chronic, impairs 
nitrogen oxide availability and endothelium-dependent vaso-
dilation and enhances the production of endothelial-derived 
vasoconstrictor prostanoids.32,33 In a recent pooled-data meta-
analysis, it was found that treatment effects of thrombectomy 
were larger at lower glucose levels.34 Together with our find-
ing, this implicates that appropriate testing whether tight glu-
cose control is needed to further improve outcomes after EVT.
Finally, ICA-T occlusions have worse collaterals com-
pared with ICA occlusions, M1 and M2 occlusion because an 
ICA-T occlusion leads to an occlusion of both the A1 segment 
Figure 2. Distribution of collateral grades per computed tomography an-
giography (CTA) acquisition phase. The contrast density in Hounsfield 
units in the unaffected hemisphere of the M1 segment of the MCA terri-
tory (arterial structure) and the confluence of sinuses (venous structure) 
was measured to determine the CTA acquisition phase. On the basis of 
these contrast measurements, all CTA studies were classified into 1 of the 
5 acquisition phases: 1 (early arterial), 2 (peak arterial), 3 (equilibrium), 4 
(peak venous), and 5 late venous).
Table 2. Univariable and Multivariable Effects of the Studied Determinants on Collateral Status
Univariable Univariable+Age and Sex Multivariable Model
 Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Age, y* 0.92 (0.87–0.97) 0.01 0.90 (0.85–0.96) <0.01 0.92 (0.86–0.98) 0.01
Male sex 0.67 (0.56–0.79) <0.001 0.65 (0.55–0.77) – 0.64 (0.53–0.76) <0.001
Systolic blood pressure 0.97 (0.94–1.01) 0.11 0.99 (0.95–1.02) –   
Diastolic blood pressure†‡ 0.94 (0.89–0.99) 0.03 0.95 (0.89–1.00) 0.07   
Glucose at baseline‡ 0.97 (0.94–0.99) 0.02 0.97 (0.94–1.00) 0.02 0.97 (0.95–1.00) 0.02
Atrial fibrillation 0.95 (0.77–1.16) 0.59     
History of hypercholesterolemia 0.90 (0.75–1.09) 0.28     
History of hypertension 0.91 (0.78–1.08) 0.29     
History of diabetes mellitus 0.84 (0.66–1.07) 0.21     
History of myocardial infarction 0.83 (0.66–1.04) 0.10 0.92 (0.73–1.16) 0.47   
History of peripheral arterial disease 0.66 (0.50–0.89) 0.01 0.71 (0.53–0.96) 0.02 0.76 (0.56–1.04) 0.09
History of ischemic stroke 0.9 (0.62–1.01) 0.06 0.82 (0.65–1.05) 0.11   
Current smoking 0.93 (0.83–1.05) 0.25     
Current statin use 0.79 (0.66–0.95) 0.01 0.86 (0.71–1.03) 0.11   
Current antiplatelet use 0.78 (0.66–0.93) 0.01 0.84 (0.70–1.00) 0.06   
Current antihypertensive use 0.84 (0.71–1.00) 0.05 0.86 (0.71–1.03) 0.09   
Extracranial carotid stenosis 1.19 (0.85–1.68) 0.32     
ICA-T occlusion 0.50 (0.41–0.61) <0.001 0.50 (0.41–0.61) <0.001 0.50 (0.41–0.61) <0.001
Time from onset to CTA§ 1.04 (0.98–1.11) 0.23     
All determinants with an association with P<0.15 in Step 1 were included in Step 2. All determinants with a significant association (P<0.05) in Step 2 were included in the 
multivariable analysis (Step 3). All models were adjusted for acquisition phase. CTA indicates computed tomography angiography; and ICA-T, intracranial carotid artery terminus.
*Per 10 y.
†Per 10 mm Hg.
‡Per 1 mmol/L.
§Per 60 min.
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of the anterior cerebral artery and the M1 segment of the 
middle cerebral artery and collateral flow may occur via the 
AComA and the cortical branches of the anterior cerebral ar-
tery to the middle cerebral artery branches. However, in this 
situation, collateral flow is dependent on a patent AComA. 
This dependency also exists in case of an ICA occlusion, but 
collateral flow may directly occur via the AComA, to the A1 
segment and subsequently to the M1 segment. In a middle ce-
rebral artery occlusion, collateral flow is independent of a pat-
ent AComA.
In single-phase CTA, collateral assessment is influenced 
by the time of the CTA snapshot. Acquiring CTA too early 
after contrast bolus administration runs the risk of underesti-
mating collateral capacity, while a delayed venous phase scan 
may hamper detection of the primary occlusion. Also, delayed 
venous phase cannot discriminate between fast and slow col-
laterals.35 Previous studies suggest single-phase CTA might 
underestimate collateral status in some patients.36,37 As collat-
eral status is used as a predictor in various prediction models 
for patients with acute ischemic stroke, this further supports 
the need to implement newer techniques like multiphase CTA, 
time-invariant CTA, or 4D-CTA.37–39
Furthermore, several factors were associated with collat-
eral status in univariable analysis but not in the multivariable 
analysis in which we adjusted for age and sex. These included 
history of myocardial infarction, history of ischemic stroke, 
the current use of antihypertensive medication, and time to 
CTA. In the final multivariable analysis, the association with 
collaterals disappeared for diastolic blood pressure, history of 
peripheral arterial disease, the use of statins, and the use of 
antiplatelets. For all these variables, this could suggest that 
cardiovascular-related factors as age and history of peripheral 
arterial disease moderate the association.15,40–42
The role of pathophysiological factors in augmenting or 
diminishing collateral status is still mostly unclear. In the liter-
ature, several factors have been studied. The presence and lu-
minal diameter of both primary collaterals (arterial segments 
of the circle of Willis) and secondary collaterals (ophthalmic 
artery and leptomeningeal vessels), formed during prenatal pe-
riod, are considered the most important determinants.14,18,43–45 
This was however beyond the scope of our current study.
Limitations
Collateral status assessment is prone to interobserver var-
iability, although all images were assessed by highly expe-
rienced and trained assessors.46 A range of different scanner 
protocols was used, which could have added to the variability. 
However, we think this heterogeneity adds to the generaliz-
ability of our study. Furthermore, all our patients underwent 
single phase CTA, which could have led to underestimation 
of collateral status in the case of delayed filling in combina-
tion with an early acquisition phase. However, the sensitivity 
analysis in which we restricted the analysis to scans acquired 
with optimal timing revealed the same results. Selection bias 
might have appeared, since we were unable to assess the col-
lateral status in 113 patients. Since multiple imputation was 
used to handle this missing data, we assume that our results 
could be safely interpreted. The golden standard for assessing 
collateral status is digital subtraction angiography. However, 
we aimed to represent the acute clinical setting, in which 
multivessel digital subtraction angiography is not performed. 
Furthermore, we did not have any information on ethnicity. It 
is known that ethnicity groups show differences in prevalence 
in acute ischemic stroke, and some studies also indicate pos-
sible differences in rates of collateralization.47,48
Finally, important to note is that the associations with col-
lateral status do not necessarily imply a causal relationship. 
For example, the association we found with higher glucose 
level could be the cause of poor collateral status but may also 
be the result of poor collateral status. Further studies to inves-
tigate the causality of associations with collateral status are 
pivotal.
Conclusions
In conclusion, this study shows that higher age, male sex, 
higher glucose levels, and occlusion of the ICA-T are asso-
ciated with poor CTA collateral grades in patients with acute 
ischemic stroke eligible for EVT. No clear modifiable deter-
minants of collateral status could be identified.
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